Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Eribulin |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Eribulin | Halaven | Antimicrotubule Agent 12 |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| Unknown unknown | triple-receptor negative breast cancer | not applicable | Eribulin | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Halaven (eribulin) inhibited epithelial-to-mesenchymal transition and increased tumor perfusion in triple-negative breast cancer cell line xenograft models (PMID: 25838395). | 25838395 |
| Unknown unknown | breast cancer | not applicable | Eribulin | Phase III | Actionable | In a randomized Phase III clinical trial, Halaven (eribulin) monotherapy demonstrated significantly improved survival (median 13.1 months) relative to treatment of physician’s choice (median 10.6 months) across 762 patients with heavily pretreated metastatic breast cancer (PMID: 21376385). | 21376385 |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status |
|---|---|---|---|---|
| NCT02788201 | Phase II | Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | Completed |
| NCT01945775 | Phase III | Gemcitabine Capecitabine Vinorelbine Talazoparib Eribulin | A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (EMBRACA) | Active, not recruiting |
| NCT01401959 | Phase II | Eribulin Eribulin + Trastuzumab | Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy | Completed |
| NCT03901339 | Phase III | Eribulin Gemcitabine Vinorelbine Capecitabine Sacituzumab govitecan-hziy | Study of IMMU-132 in HR+/HER2- MBC (TROPICS-02) | Recruiting |
| NCT02555657 | Phase III | Pembrolizumab Eribulin Gemcitabine Vinorelbine Capecitabine | Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) | Active, not recruiting |
| NCT03051659 | Phase II | Eribulin Eribulin + Pembrolizumab | A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer | Active, not recruiting |
| NCT02492711 | Phase III | Vinorelbine Capecitabine Gemcitabine Trastuzumab Eribulin Margetuximab | Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer | Active, not recruiting |
| NCT02000622 | Phase III | Olaparib Vinorelbine Eribulin Capecitabine | Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD) | Active, not recruiting |
| NCT01744340 | Phase Ib/II | Eribulin Cetuximab | A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer | Completed |
| NCT02419495 | Phase I | Cyclophosphamide Pemetrexed Eribulin Selinexor Carboplatin Paclitaxel Topotecan Dexamethasone Doxorubicin | Selinexor in Combination With Standard Chemotherapy | Recruiting |
| NCT02481050 | Phase II | Eribulin | Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer | Completed |
| NCT03734029 | Phase III | Fam-trastuzumab deruxtecan-nxki Nab-paclitaxel Capecitabine Paclitaxel Gemcitabine Eribulin | DS-8201a Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] | Recruiting |
| NCT03786094 | Phase III | Eribulin Eribulin + POL6326 | Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer | Recruiting |
| NCT03441360 | Phase II | Eribulin | Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) | Recruiting |
| NCT01912963 | Phase II | Eribulin Pertuzumab Trastuzumab | Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer | Terminated |
| NCT03056599 | Gemcitabine Interferon alpha-2b Doxorubicin Pembrolizumab Eribulin interferon gamma Ipilimumab Trabectedin Aldesleukin Bortezomib Docetaxel | Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma | Recruiting | |
| NCT01596751 | Phase Ib/II | Eribulin Pexidartinib | Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer | Completed |
CKB BOOST